Anti-CD6 mAbs for the treatment of psoriasis

Abstract

Introduction: Psoriasis is a chronic inflammatory skin condition known to affect about 1%-3% of the global population. Psoriasis can be a serious burden to the patients, having deleterious effect on their physical, social and mental wellbeing. Systemic therapies consisting of methotrexate, cyclosporine, acitretin, PUVA, etc. used in moderate to severe psoriasis, are associated with end organ toxicity with long term use.

Areas covered: Role of Itolizumab, an anti CD6 biologic in regulation of lymphocyte development, selection, activation and differentiation in the set-up of psoriasis. We performed a literature review by searching online databases including PubMed and Google Scholar.

Expert opinion: There is emerging evidence to implicate CD6 and its ligands in the pathogenesis and potentially the treatment of inflammatory and autoimmune diseases, like psoriasis and multiple sclerosis. Its potential advantage over anti TNF biologics in predisposing to lesser risk of tuberculosis and other serious systemic infections or adverse effects makes it a potential valuable asset in the armamentarium of anti-psoriasis drugs.

Keywords: Anti CD6; Itolizumab; biologics; psoriasis.